公开(公告)号：US20120276562A1

公开(公告)日：2012-11-01

申请号：US13502198

申请日：2010-10-13

申请人： Wataru Kikuchi ,  Momoe Sato ,  Kenta Noda ,  Iwao Kiyokawa ,  Toshihide Miura ,  Ryo Kojima ,  Fumio Nomura ,  Kazuyuki Sogawa

发明人： Wataru Kikuchi ,  Momoe Sato ,  Kenta Noda ,  Iwao Kiyokawa ,  Toshihide Miura ,  Ryo Kojima ,  Fumio Nomura ,  Kazuyuki Sogawa

IPC分类号： G01N33/566 ,  C07K16/00 ,  G01N21/47 ,  G01N33/545 ,  G01N21/78

CPC分类号： G01N33/6893 ,  C07K16/36 ,  C07K2317/34 ,  G01N33/5308 ,  G01N2333/75 ,  G01N2800/08

摘要： Disclosed is an immunoassay method whereby a 5.9 kDa peptide which results from the degradation of the α-E chain and α chain of human fibrinogens and which is used as a peptide marker for diagnosing hepatic disease can be specifically assayed in a biological sample containing contaminating peptides by bringing antibodies that recognize the N terminal of said peptide marker and antibodies that recognize the C terminal of said peptide marker into contact with said peptide marker, forming immune complexes of said peptide marker and the two antibodies, and immunoassaying the obtained immune complexes.

摘要翻译： 公开了一种免疫测定方法，其中可以在含有污染肽的生物样品中特异性地测定由于人纤维蛋白原的α-E链和α链的降解而产生的并用作诊断肝脏疾病的肽标志物的5.9kDa肽 通过将识别所述肽标记的N末端的抗体和识别所述肽标记的C末端的抗体与所述肽标记接触，形成所述肽标记和两种抗体的免疫复合物，并免疫测定所获得的免疫复合物。

公开(公告)号：US09017959B2

公开(公告)日：2015-04-28

申请号：US13502198

申请日：2010-10-13

申请人： Wataru Kikuchi ,  Momoe Sato ,  Kenta Noda ,  Iwao Kiyokawa ,  Toshihide Miura ,  Ryo Kojima ,  Fumio Nomura ,  Kazuyuki Sogawa

发明人： Wataru Kikuchi ,  Momoe Sato ,  Kenta Noda ,  Iwao Kiyokawa ,  Toshihide Miura ,  Ryo Kojima ,  Fumio Nomura ,  Kazuyuki Sogawa

IPC分类号： G01N33/53 ,  G01N33/543 ,  G01N33/68 ,  C07K16/36

CPC分类号： G01N33/6893 ,  C07K16/36 ,  C07K2317/34 ,  G01N33/5308 ,  G01N2333/75 ,  G01N2800/08

摘要： Disclosed is an immunoassay method whereby a 5.9 kDa peptide which results from the degradation of the α-E chain and α chain of human fibrinogens and which is used as a peptide marker for diagnosing hepatic disease can be specifically assayed in a biological sample containing contaminating peptides by bringing antibodies that recognize the N terminal of said peptide marker and antibodies that recognize the C terminal of said peptide marker into contact with said peptide marker, forming immune complexes of said peptide marker and the two antibodies, and immunoassaying the obtained immune complexes.

摘要翻译： 公开了一种免疫测定方法，其中可以在含有污染肽的生物样品中特异性地测定由于人纤维蛋白原的α-E链和α链的降解而产生的并用作诊断肝脏疾病的肽标志物的5.9kDa肽 通过将识别所述肽标记的N末端的抗体和识别所述肽标记的C末端的抗体与所述肽标记接触，形成所述肽标记和两种抗体的免疫复合物，并免疫测定所获得的免疫复合物。

公开(公告)号：US20120282638A1

公开(公告)日：2012-11-08

申请号：US13521084

申请日：2011-01-18

申请人： Ryo Kojima ,  Kenta Noda ,  Masanori Seimiya ,  Kazuyuki Sogawa ,  Fumio Nomura

发明人： Ryo Kojima ,  Kenta Noda ,  Masanori Seimiya ,  Kazuyuki Sogawa ,  Fumio Nomura

IPC分类号： G01N33/574 ,  C07K16/18 ,  C07K14/46

CPC分类号： G01N33/6854 ,  G01N33/564 ,  G01N33/57438 ,  G01N33/57484 ,  G01N2333/47 ,  G01N2333/90

摘要： An autoantibody against Ku86 can be measured by reacting the autoantibody contained in a sample with a Ku86 antigen (which serves as a reagent) to produce an immune complex of the autoantibody and the Ku86 antigen and measuring the immune complex using a labeled anti-human immunoglobulin antibody. The measurement of the autoantibody enables the determination of primary hepatocellular carcinoma.

摘要翻译： 可以通过使样品中包含的自身抗体与Ku86抗原（其用作试剂）反应以产生自身抗体和Ku86抗原的免疫复合物并使用标记的抗人免疫球蛋白测量免疫复合物来测量针对Ku86的自身抗体 抗体。 自身抗体的测定能够确定原发性肝细胞癌。

公开(公告)号：US20120309034A1

公开(公告)日：2012-12-06

申请号：US13577530

申请日：2011-02-07

申请人： Ryo Kojima ,  Kenta Noda ,  Masanori Seimiya ,  Kazuyuki Sogawa ,  Fumio Nomura

发明人： Ryo Kojima ,  Kenta Noda ,  Masanori Seimiya ,  Kazuyuki Sogawa ,  Fumio Nomura

IPC分类号： G01N21/59 ,  G01N33/574 ,  G01N33/566

CPC分类号： G01N33/57484 ,  G01N33/564 ,  G01N2333/922

摘要： A reaginic antibody of Ku86 and a substance capable of binding with the autoantibody of Ku86 are acted on a complex of Ku86 and the autoantibody thereof in a subject. Said complex can be measured by measuring the obtained immune complex of the aforementioned complex, reaginic antibody, and substance capable of binding with the autoantibody of Ku86. As a consequence, it is possible to determine whether the cancer is a primary hepatoma, colon cancer, stomach cancer, pancreatic cancer, breast cancer, lung cancer, or an esophageal cancer.

摘要翻译： Ku86的反应性抗体和能够与Ku86的自身抗体结合的物质作用于受试者中Ku86和其自身抗体的复合物。 所述复合物可以通过测量获得的上述复合物，反应性抗体和能够与Ku86自身抗体结合的物质的免疫复合物来测量。 因此，可以确定癌症是原发性肝癌，结肠癌，胃癌，胰腺癌，乳腺癌，肺癌或食管癌。

公开(公告)号：US20130089871A1

公开(公告)日：2013-04-11

申请号：US13703740

申请日：2011-06-13

申请人： Fumio Nomura ,  Motoi Nishimura ,  Katsuhiro Katayama ,  Iwao Kiyokawa

发明人： Fumio Nomura ,  Motoi Nishimura ,  Katsuhiro Katayama ,  Iwao Kiyokawa

IPC分类号： C12Q1/52

CPC分类号： C12Q1/52 ,  G01N33/573 ,  G01N2333/91188 ,  G01N2800/085

摘要： The detection of a non-alcoholic steatohepatitis patient and the accurate discrimination between a normal person and a non-alcoholic steatohepatitis patient can be achieved by measuring alanine-glyoxylate amino transferase in a sample.

摘要翻译： 非酒精性脂肪性肝炎患者的检测以及正常人和非酒精性脂肪性肝炎患者之间的准确辨别可以通过测定样品中的丙氨酸 - 乙醛酸氨基转移酶来实现。

公开(公告)号：US07517951B2

公开(公告)日：2009-04-14

申请号：US10538916

申请日：2003-12-24

申请人： Fumio Nomura ,  Kazuyuki Sogawa ,  Takeshi Tomonaga ,  Takenori Ochiai ,  Hideaki Shimada ,  Tatsuya Ohashi ,  Katsuhiro Katayama

发明人： Fumio Nomura ,  Kazuyuki Sogawa ,  Takeshi Tomonaga ,  Takenori Ochiai ,  Hideaki Shimada ,  Tatsuya Ohashi ,  Katsuhiro Katayama

IPC分类号： A61K38/00 ,  A61K35/14

CPC分类号： G01N33/6893 ,  G01N2333/75 ,  G01N2333/775 ,  G01N2800/08

摘要： Using the protein chip technology, biological samples such as sera are subjected to proteome analysis. Thus, a protein which is a human fibrinogen α-E chain decomposition product and has a molecular weight of 5,900, a protein which is an apolipoprotein AII decomposition product and has a molecular weight of 7,800, and a protein which is an apolipoprotein AI decomposition product and has a molecular weight of 28,000, each showing an increase or a decrease with the habit of drinking, are newly found out. By detecting or quantifying these proteins, a liver disease in a subject such as one having a problem of drinking can be diagnosed at the early stage.

摘要翻译： 使用蛋白质芯片技术，生物样品如血清进行蛋白质组分析。 因此，作为人纤维蛋白原α-E链分解产物的分子量为5900的蛋白质，作为载脂蛋白AII分解产物，分子量为7800的蛋白质，以及作为载脂蛋白AI分解产物的蛋白质 并且新发现的分子量为28,000，分别显示饮酒习惯的增加或减少。 通过检测或定量这些蛋白质，可以在早期诊断患有饮酒问题的受试者的肝脏疾病。

公开(公告)号：US07781180B2

公开(公告)日：2010-08-24

申请号：US12379904

申请日：2009-03-04

申请人： Fumio Nomura ,  Kazuyuki Sogawa ,  Takeshi Tomonaga ,  Takenori Ochiai ,  Hideaki Shimada ,  Tatsuya Ohashi ,  Katsuhiro Katayama

发明人： Fumio Nomura ,  Kazuyuki Sogawa ,  Takeshi Tomonaga ,  Takenori Ochiai ,  Hideaki Shimada ,  Tatsuya Ohashi ,  Katsuhiro Katayama

IPC分类号： A61K38/00 ,  A61K35/14 ,  G01N33/53

CPC分类号： G01N33/6893 ,  G01N2333/75 ,  G01N2333/775 ,  G01N2800/08

摘要： Using the protein chip technology, biological samples such as sera are subjected to proteome analysis. Thus, a protein which is a human fibrinogen α-E chain decomposition product and has a molecular weight of 5,900, a protein which is an apolipoprotein AII decomposition product and has a molecular weight of 7,800, and a protein which is an apolipoprotein AI decomposition product and has a molecular weight of 28,000, each showing an increase or a decrease with the habit of drinking, are newly found out. By detecting or quantifying these proteins, a liver disease in a subject such as one having a problem of drinking can be diagnosed at the early stage.

摘要翻译： 使用蛋白质芯片技术，生物样品如血清进行蛋白质组分析。 因此，作为人纤维蛋白原α-E链分解产物，分子量为5900的蛋白质，作为载脂蛋白AII分解产物，分子量为7800的蛋白质，以及作为载脂蛋白AI分解产物的蛋白质 并且新发现的分子量为28,000，分别显示饮酒习惯的增加或减少。 通过检测或定量这些蛋白质，可以在早期诊断患有饮酒问题的受试者的肝脏疾病。

公开(公告)号：US20060116504A1

公开(公告)日：2006-06-01

申请号：US10538916

申请日：2003-12-24

申请人： Fumio Nomura ,  Kazuyuki Sogawa ,  Takeshi Tomonaga ,  Takenori Ochiai ,  Hideaki Shimada ,  Tatsuya Oshashi ,  Katsuhiro Katayama

发明人： Fumio Nomura ,  Kazuyuki Sogawa ,  Takeshi Tomonaga ,  Takenori Ochiai ,  Hideaki Shimada ,  Tatsuya Oshashi ,  Katsuhiro Katayama

IPC分类号： C07K14/47 ,  G01N33/567

CPC分类号： G01N33/6893 ,  G01N2333/75 ,  G01N2333/775 ,  G01N2800/08

摘要： Using the protein chip technology, biological samples such as sera are subjected to proteome analysis. Thus, a protein which is a human fibrinogen α-E chain decomposition product and has a molecular weight of 5,900, a protein which is an apolipoprotein AII decomposition product and has a molecular weight of 7,800, and a protein which is an apolipoprotein AI decomposition product and has a molecular weight of 28,000, each showing an increase or a decrease with the habit of drinking, are newly found out. By detecting or quantifying these proteins, a liver disease in a subject such as one having a problem of drinking can be diagnosed at the early stage.

公开(公告)号：US08563235B2

公开(公告)日：2013-10-22

申请号：US12917570

申请日：2010-11-02

申请人： Shintaro Kikkawa ,  Kazuyuki Sogawa ,  Osamu Yokosuka ,  Fumio Nomura

发明人： Shintaro Kikkawa ,  Kazuyuki Sogawa ,  Osamu Yokosuka ,  Fumio Nomura

IPC分类号： C12Q1/00 ,  C12Q1/56 ,  C12N9/74

CPC分类号： G01N33/6851 ,  G01N33/57407 ,  H01J49/00

摘要： A method of detecting an abnormal amount of a biomarker associated with biliary tract cancer in a subject can comprise: a) quantitating an amount of a fragment of prothrombin having an m/z value of about 4204 m/z in a biological sample from the subject; and b) comparing the quantitated value obtained in (a) with a threshold value.

摘要翻译： 检测受试者中与胆道癌相关的生物标志物的异常量的方法可以包括：a）定量来自受试者的生物样品中具有约4204m / z的m / z值的凝血酶原的片段的量 ; 和b）将（a）中获得的定量值与阈值进行比较。

公开(公告)号：US20110108722A1

公开(公告)日：2011-05-12

申请号：US12917570

申请日：2010-11-02

申请人： Shintaro Kikkawa ,  Kazuyuki Sogawa ,  Osamu Yokosuka ,  Fumio Nomura

发明人： Shintaro Kikkawa ,  Kazuyuki Sogawa ,  Osamu Yokosuka ,  Fumio Nomura

IPC分类号： H01J49/00

CPC分类号： G01N33/6851 ,  G01N33/57407 ,  H01J49/00

摘要： A method of detecting an abnormal amount of a biomarker associated with biliary tract cancer in a subject can comprise: a) quantitating an amount of a fragment of prothrombin having an m/z value of about 4204 m/z in a biological sample from the subject; and b) comparing the quantitated value obtained in (a) with a threshold value.

摘要翻译： 检测受试者中与胆道癌相关的生物标志物的异常量的方法可以包括：a）定量来自受试者的生物样品中具有约4204m / z的m / z值的凝血酶原的片段的量 ; 和b）将（a）中获得的定量值与阈值进行比较。